Get access

Neuropeptide Y suppresses absence seizures in a genetic rat model primarily through effects on Y2 receptors

Authors

  • Margaret J. Morris,

    1. Department of Physiology and Pharmacology, University of New South Wales, Kensington, New South Wales, Australia, 2052
    2. Department of Pharmacology, The University of Melbourne, Victoria, Australia, 3010
    Search for more papers by this author
  • Emma Gannan,

    1. Departments of Medicine and Surgery, The Royal Melbourne Hospital, The University of Melbourne, Victoria, Australia, 3050
    Search for more papers by this author
  • Leanne M. Stroud,

    1. Departments of Medicine and Surgery, The Royal Melbourne Hospital, The University of Melbourne, Victoria, Australia, 3050
    Search for more papers by this author
  • Annette G. Beck-Sickinger,

    1. Institute of Biochemistry, University of Leipzig, Leipzig, Germany
    Search for more papers by this author
  • Terence J. O'Brien

    1. Departments of Medicine and Surgery, The Royal Melbourne Hospital, The University of Melbourne, Victoria, Australia, 3050
    2. Department of Neurology, The Royal Melbourne Hospital, Parkville, Victoria, Australia, 3050
    Search for more papers by this author

Professor M. Morris, 1Department of Physiology and Pharmacology, as above.
E-mail: m.morris@unsw.edu.au

Abstract

Neuropeptide Y (NPY) potently suppresses absence seizures in a model of genetic generalized epilepsy, genetic absence epilepsy rats of Strasbourg (GAERS). Here we investigated the Y-receptor subtype(s) on which NPY exerts this anti-absence effect. A dual in vivo approach was used: the cumulative duration of seizures was quantified in adult male GAERS in 90-min electroencephalogram recordings following intracerebroventricular (i.c.v.) injection of: (i) subtype-selective agonists of Y1 ([Leu31Pro34]NPY, 2.5 nmol), Y2 (Ac[Leu28,31]NPY24–36, 3 nmol), Y5 receptors [hPP1−17,Ala31,Aib32]NPY, 4 nmol), NPY (3 nmol) or vehicle; and following (ii) i.c.v. injection of antagonists of Y1 (BIBP3226, 20 nmol), Y2 (BIIE0246, 20 nmol) and Y5 (NPY5RA972, 20 nmol) receptors or vehicle, followed by NPY (3 nmol). Injection of the Y1- and Y5-selective agonists resulted in significantly less mean seizure suppression (37.4% and 53.9%, respectively) than NPY (83.2%; P < 0.05), while the Y2 agonist had similar effects to NPY (62.3% suppression, P = 0.57). Food intake was not increased following injection of the Y2 agonist, while significant increases in food intake were seen following NPY and the other Y-subtype agonists. Compared with vehicle, NPY injection suppressed seizures following the Y1 and Y5 antagonists (45.3% and 80.1%, respectively, P < 0.05), but not following the Y2 antagonist (5.1% suppression, P = 0.46). We conclude that NPY Y2 receptors are more important than Y1 and Y5 receptors in mediating the effect of NPY to suppress absence seizures in a genetic rat model. Y2 receptor agonists may represent targets for novel drugs against genetic generalized epilepsies without resulting in appetite stimulation.

Ancillary